Teva (TEVA) Q2 2026 earnings review
Innovative Surge Masked by Generics Cliff and M&A Distortion
Teva's 'Pivot to Growth' narrative is colliding with the reality of its patent cliffs. While the trio of innovative brands (AUSTEDO, AJOVY, UZEDY) surged 43% YoY to over $1 billion globally, U.S. Generics plummeted 31%, pulling total company revenue down 1% YoY to $4.14B. The bottom line was aggressively distorted by the Emalex acquisition, generating a massive $724M in-process R&D (IPR&D) charge that temporarily crushed Non-GAAP EPS to $0.02 from $0.66 a year ago. Despite the messy optics, underlying cash generation remains robust ($622M Free Cash Flow), and management confidently raised full-year revenue guidance for all three key innovative brands.
🐂 Bull Case
AUSTEDO, AJOVY, and UZEDY are accelerating rapidly, now representing over 25% of total revenue. Their higher profitability drove underlying non-GAAP gross margins up to 55.4%, validating the strategic pivot.
Despite a GAAP net loss of $576M driven by the Emalex acquisition, Free Cash Flow accelerated to $622M (up from $476M YoY), keeping the 2027 deleveraging targets fully intact.
🐻 Bear Case
U.S. Generics collapsed 31% YoY. Until the generic Revlimid patent cliff is fully lapped, the consolidated top line will continue to obscure the growth of the branded portfolio.
The Emalex deal wiped out quarterly operating profits, and management expects $0.77B in total related expenses for 2026, drastically reducing near-term EPS and making financial screening metrics screen poorly for the remainder of the year.
⚖️ Verdict: ⚪
Neutral. The underlying mix shift from low-margin generics to high-margin branded products is highly encouraging, but the severe near-term drag from generic Revlimid and M&A accounting noise makes the current financial picture look worse than the operational reality.
Key Themes
AUSTEDO and LAI Franchise Accelerating
Teva's core growth engines are significantly outperforming expectations. AUSTEDO U.S. revenues grew 37% YoY to $676M, and UZEDY revenues grew 43% to $77M. This strong volume and favorable net-pricing realization prompted management to raise the full-year 2026 outlook for both drugs.
Narrative vs Reality: The U.S. Generics Cliff
While management repeatedly highlights the success of the 'Pivot to Growth', a specific data point contradicts the broader growth narrative: consolidated net revenue reversed to a 1% decline this quarter. This was entirely caused by U.S. Generics, which plunged 31% YoY to $660M due to the roll-off of generic Revlimid (lenalidomide) revenues, erasing the massive gains made by the innovative portfolio.
Emalex M&A Distorts Operating Margins
The $700M acquisition of Emalex Biosciences triggered a $724M in-process R&D charge. Consequently, Non-GAAP operating margin abruptly reversed from a healthy 27.1% a year ago to just 9.0%. While this is a non-cash accounting effect, it completely obscures Teva's operational leverage and cost-saving progress.
Innovative Pipeline Maturation
Teva is actively expanding its future revenue base. An NDA for ecopipam (acquired via Emalex) for pediatric Tourette syndrome was submitted in June 2026. Concurrently, the EMA accepted the MAA for olanzapine LAI for schizophrenia, setting the stage for a critical U.S. launch expected in Q4 2026.
Biosimilars Scaling as a Generics Offset
To eventually plug the hole left by generic Revlimid, Teva is aggressively scaling its biosimilars business. The company launched AHZANTIVE (aflibercept, biosimilar to Eylea) in Europe and signed a global licensing agreement for a biosimilar to Ocrevus. Management reiterated their target of hitting $800M in biosimilar revenue by 2027.
API Divestiture Remains a Drag
Revenue from API sales to third parties fell 12% YoY to $118M. Teva previously announced intentions to divest the TAPI business, but lower demand and price reductions are currently hurting the segment's financials, keeping it as a persistent, low-growth distraction from the core branded strategy.
FX Hedging Masks Further Weakness
Macroeconomic factors provided an artificial boost to the top line. Exchange rate movements, including hedging effects, positively impacted Q2 2026 revenues by $85 million. Without this macro tailwind, the consolidated revenue decline would have been closer to 3%.
Other KPIs
Accelerating from $476 million in Q2 2025. This proves that the massive GAAP Net Loss was an accounting artifact of the Emalex acquisition. The business is generating substantial cash, driven by higher operating cash flow ($411M) and efficient working capital management through the EU securitization program.
Stable/Declining. With Total Debt at $16.59B and Cash at $3.66B, net debt continues its downward trajectory. The company successfully shifted a portion of long-term debt to short-term ($4.5B now short-term vs $1.82B at year-end 2025), maintaining an average debt maturity of 5.1 years.
Accelerating slightly from 54.6% in Q2 2025. This is the purest indicator of the Pivot to Growth strategy working: as high-margin products like AUSTEDO and AJOVY replace low-margin legacy generics, the fundamental profitability of the products sold is expanding.
Guidance
Stable. The lower end of the range was raised by $100M from prior guidance, but the midpoint ($16.675B) implies a slight deceleration compared to 2025 actuals ($17.3B) as the company absorbs the roughly $1.1B headwind from the loss of generic Revlimid revenues.
Decelerating. Maintained from April, this guidance is heavily suppressed by the Emalex acquisition, which includes a negative $0.66 per share impact. Without this M&A drag, implied EPS would have been significantly higher, closer to the 2025 actuals of $2.93.
Decelerating YoY, entirely due to the inclusion of ~$0.77 billion in expected 2026 expenses related to the Emalex transaction. The core operating leverage remains intact underneath this one-time strategic investment.
Stable. Reaffirmed from prior guidance, showing that the upfront $700M cash outlay for Emalex is easily absorbed by the company's strong underlying cash generation capabilities.
Key Questions
Revlimid Trough Timing
With U.S. Generics down 31% YoY to $660M, have we officially hit the trough for the generic Revlimid cliff, or should investors expect further sequential deterioration in this segment throughout H2 2026?
Ecopipam Commercial Ramp
The Emalex deal wiped out Q2 operating profits and acts as a $0.66 drag on 2026 EPS. Given the pediatric Tourette syndrome market dynamics, how quickly do you expect ecopipam to become accretive to earnings post-launch?
TAPI Divestiture Update
API sales declined 12% this quarter. Given the previously stalled sale process for the TAPI business, what is the current realistic timeline for divesting this asset so management can fully focus on the innovative pipeline?
Biosimilar Margin Profile
As the biosimilar portfolio scales toward the $800M target with new launches like AHZANTIVE, how do the gross margins of these partnered biosimilars compare to the legacy U.S. generics business they are replacing?